初诊2型糖尿病患者罗格列酮治疗对颈动脉内膜中层厚度的影响  

Effects of rosiglitazone on carotid intima-media thickness in newly diagnosed type 2 diabetic patients

作　　者：鞠巍[1] 赵晓娟[1] 

机构地区：[1]中国医科大学,辽宁沈阳110001

出　　处：《中国医药导报》2008年第21期29-30,共2页China Medical Herald

摘　　要：目的:观察初诊2型糖尿病患者颈动脉内膜中层厚度(IMT)的变化,探讨罗格列酮的抗动脉粥样硬化作用及其机制。方法:初诊2型糖尿病患者91例随机分为罗格列酮治疗组和对照组。高分辨超声测量IMT,治疗12周后复测IMT,比较治疗前后的变化。结果:罗格列酮治疗组治疗后IMT值显著降低(P<0.05)。对照组治疗前后无显著性差异(P>0.05)。两组间治疗前后IMT值比较差异具有显著性(P<0.05)。结论:罗格列酮能显著降低初诊2型糖尿病患者IMT水平,并可能抑制糖尿病患者早期动脉粥样硬化的发生和发展。Objective：To investigate the change of carotid intima-media thickness（IMT） in newly diagnosed type 2 diabetic patients and anti-atherosclerosis effects of rosiglitazone. Methods： Ninety-one newly diagnosed type 2 diabetic patients were divided randomly into rosiglitazone treatment group and control group. They all received the treatment for 12 weeks. The IMT was measured by high resolution ultrasonography, and the changes of IMT were compared. Results：After treatment with rosiglitazone, IMT levels decreased significantly （P〈0.05）.There was no obvious change in the control group before and after treatment （P〉0.05）.The changes of IMT in the two groups were significant （P〈0.05）. Conclusion：IMT can be reduced significantly in the newly diagnosed type 2 diabetic patients after being treated with rosiglitazone,which maybe delay the occurrence and development of atherosclerosis.

关 键 词：罗格列酮 2型糖尿病 颈动脉内膜中层厚度 噻唑烷二酮 动脉粥样硬化 

分 类 号：R587.1[医药卫生—内分泌]